PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer

Prashanth K.B. Nagesh, Nia R. Johnson, Vijaya K.N. Boya, Pallabita Chowdhury, Shadi F. Othman, Vahid Khalilzad-Sharghi, Bilal Hafeez, Aditya Ganju, Sheema Khan, Stephen W. Behrman, Nadeem Zafar, Subhash Chauhan, Meena Jaggi, Murali Yallapu

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC). However, adverse side effects and problems associated with chemo-resistance limit its therapeutic outcome in clinical settings. A targeted nanoparticle system to improve its delivery to and activity at the tumor site could be an attractive strategy for PC therapy. Therefore, the objective of this study was to develop and determine the anti-cancer efficacy of a novel docetaxel loaded, prostate specific membrane antigen (PSMA) targeted superparamagnetic iron oxide nanoparticle (SPION) (J591-SPION-Dtxl) formulation for PC therapy. Our results showed the SPION-Dtxl formulation exhibits an optimal particle size and zeta potential, which can efficiently be internalized in PC cells. SPION-Dtxl exhibited potent anti-cancer efficacy via induction of the expression of apoptosis associated proteins, downregulation of anti-apoptotic proteins, and inhibition of chemo-resistance associated protein in PC cell lines. J591-SPION-Dtxl exhibited a profound uptake in C4-2 (PSMA+) cells compared to PC-3 (PSMA-) cells. A similar targeting potential was observed in ex-vivo studies in C4-2 tumors but not in PC-3 tumors, suggesting its tumor specific targeting. Overall, this study suggests that a PSMA antibody functionalized SPION-Dtxl formulation can be highly useful for targeted PC therapy.

Original languageEnglish (US)
Pages (from-to)8-20
Number of pages13
JournalColloids and Surfaces B: Biointerfaces
Volume144
DOIs
StatePublished - Aug 1 2016

Fingerprint

docetaxel
antigens
Antigens
Iron oxides
iron oxides
Nanoparticles
Prostatic Neoplasms
cancer
membranes
Membranes
nanoparticles
Tumors
tumors
Proteins
Neoplasms
therapy
proteins
formulations
Apoptosis Regulatory Proteins
Cell death

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Surfaces and Interfaces
  • Physical and Theoretical Chemistry
  • Colloid and Surface Chemistry

Cite this

PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. / Nagesh, Prashanth K.B.; Johnson, Nia R.; Boya, Vijaya K.N.; Chowdhury, Pallabita; Othman, Shadi F.; Khalilzad-Sharghi, Vahid; Hafeez, Bilal; Ganju, Aditya; Khan, Sheema; Behrman, Stephen W.; Zafar, Nadeem; Chauhan, Subhash; Jaggi, Meena; Yallapu, Murali.

In: Colloids and Surfaces B: Biointerfaces, Vol. 144, 01.08.2016, p. 8-20.

Research output: Contribution to journalArticle

Nagesh, Prashanth K.B. ; Johnson, Nia R. ; Boya, Vijaya K.N. ; Chowdhury, Pallabita ; Othman, Shadi F. ; Khalilzad-Sharghi, Vahid ; Hafeez, Bilal ; Ganju, Aditya ; Khan, Sheema ; Behrman, Stephen W. ; Zafar, Nadeem ; Chauhan, Subhash ; Jaggi, Meena ; Yallapu, Murali. / PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. In: Colloids and Surfaces B: Biointerfaces. 2016 ; Vol. 144. pp. 8-20.
@article{6a050cad25b14f4bad6e6570b13c67db,
title = "PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer",
abstract = "Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC). However, adverse side effects and problems associated with chemo-resistance limit its therapeutic outcome in clinical settings. A targeted nanoparticle system to improve its delivery to and activity at the tumor site could be an attractive strategy for PC therapy. Therefore, the objective of this study was to develop and determine the anti-cancer efficacy of a novel docetaxel loaded, prostate specific membrane antigen (PSMA) targeted superparamagnetic iron oxide nanoparticle (SPION) (J591-SPION-Dtxl) formulation for PC therapy. Our results showed the SPION-Dtxl formulation exhibits an optimal particle size and zeta potential, which can efficiently be internalized in PC cells. SPION-Dtxl exhibited potent anti-cancer efficacy via induction of the expression of apoptosis associated proteins, downregulation of anti-apoptotic proteins, and inhibition of chemo-resistance associated protein in PC cell lines. J591-SPION-Dtxl exhibited a profound uptake in C4-2 (PSMA+) cells compared to PC-3 (PSMA-) cells. A similar targeting potential was observed in ex-vivo studies in C4-2 tumors but not in PC-3 tumors, suggesting its tumor specific targeting. Overall, this study suggests that a PSMA antibody functionalized SPION-Dtxl formulation can be highly useful for targeted PC therapy.",
author = "Nagesh, {Prashanth K.B.} and Johnson, {Nia R.} and Boya, {Vijaya K.N.} and Pallabita Chowdhury and Othman, {Shadi F.} and Vahid Khalilzad-Sharghi and Bilal Hafeez and Aditya Ganju and Sheema Khan and Behrman, {Stephen W.} and Nadeem Zafar and Subhash Chauhan and Meena Jaggi and Murali Yallapu",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.colsurfb.2016.03.071",
language = "English (US)",
volume = "144",
pages = "8--20",
journal = "Colloids and Surfaces B: Biointerfaces",
issn = "0927-7765",
publisher = "Elsevier",

}

TY - JOUR

T1 - PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer

AU - Nagesh, Prashanth K.B.

AU - Johnson, Nia R.

AU - Boya, Vijaya K.N.

AU - Chowdhury, Pallabita

AU - Othman, Shadi F.

AU - Khalilzad-Sharghi, Vahid

AU - Hafeez, Bilal

AU - Ganju, Aditya

AU - Khan, Sheema

AU - Behrman, Stephen W.

AU - Zafar, Nadeem

AU - Chauhan, Subhash

AU - Jaggi, Meena

AU - Yallapu, Murali

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC). However, adverse side effects and problems associated with chemo-resistance limit its therapeutic outcome in clinical settings. A targeted nanoparticle system to improve its delivery to and activity at the tumor site could be an attractive strategy for PC therapy. Therefore, the objective of this study was to develop and determine the anti-cancer efficacy of a novel docetaxel loaded, prostate specific membrane antigen (PSMA) targeted superparamagnetic iron oxide nanoparticle (SPION) (J591-SPION-Dtxl) formulation for PC therapy. Our results showed the SPION-Dtxl formulation exhibits an optimal particle size and zeta potential, which can efficiently be internalized in PC cells. SPION-Dtxl exhibited potent anti-cancer efficacy via induction of the expression of apoptosis associated proteins, downregulation of anti-apoptotic proteins, and inhibition of chemo-resistance associated protein in PC cell lines. J591-SPION-Dtxl exhibited a profound uptake in C4-2 (PSMA+) cells compared to PC-3 (PSMA-) cells. A similar targeting potential was observed in ex-vivo studies in C4-2 tumors but not in PC-3 tumors, suggesting its tumor specific targeting. Overall, this study suggests that a PSMA antibody functionalized SPION-Dtxl formulation can be highly useful for targeted PC therapy.

AB - Docetaxel (Dtxl) is currently the most common therapeutic option for prostate cancer (PC). However, adverse side effects and problems associated with chemo-resistance limit its therapeutic outcome in clinical settings. A targeted nanoparticle system to improve its delivery to and activity at the tumor site could be an attractive strategy for PC therapy. Therefore, the objective of this study was to develop and determine the anti-cancer efficacy of a novel docetaxel loaded, prostate specific membrane antigen (PSMA) targeted superparamagnetic iron oxide nanoparticle (SPION) (J591-SPION-Dtxl) formulation for PC therapy. Our results showed the SPION-Dtxl formulation exhibits an optimal particle size and zeta potential, which can efficiently be internalized in PC cells. SPION-Dtxl exhibited potent anti-cancer efficacy via induction of the expression of apoptosis associated proteins, downregulation of anti-apoptotic proteins, and inhibition of chemo-resistance associated protein in PC cell lines. J591-SPION-Dtxl exhibited a profound uptake in C4-2 (PSMA+) cells compared to PC-3 (PSMA-) cells. A similar targeting potential was observed in ex-vivo studies in C4-2 tumors but not in PC-3 tumors, suggesting its tumor specific targeting. Overall, this study suggests that a PSMA antibody functionalized SPION-Dtxl formulation can be highly useful for targeted PC therapy.

UR - http://www.scopus.com/inward/record.url?scp=84962158502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962158502&partnerID=8YFLogxK

U2 - 10.1016/j.colsurfb.2016.03.071

DO - 10.1016/j.colsurfb.2016.03.071

M3 - Article

VL - 144

SP - 8

EP - 20

JO - Colloids and Surfaces B: Biointerfaces

JF - Colloids and Surfaces B: Biointerfaces

SN - 0927-7765

ER -